Case Report: ALK rearranged locally advanced lung adenocarcinoma showing inconsistent radiographic findings and pathological responses during neoadjuvant alectinib therapy

Alectinib has been approved as first-line treatment for anaplastic lymphoma kinase (ALK)-positive non-small cell lung carcinoma. Oncologists are also exploring the possibility of applying alectinib in the perioperative period. Here, we present a patient with locally advanced lung adenocarcinoma asso...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Peijun Cao, Qingchun Zhao, Yongwen Li, Ruifeng Shi, Guangsheng Zhu, Zihe Zhang, Hongbing Zhang, Minghui Liu, Sen Wei, Hongyu Liu, Jun Chen
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2023-08-01
Colecção:	Frontiers in Pharmacology
Assuntos:	EML4-ALK fusion gene pulmonary adenocarcinoma neoadjuvant therapy alectinib pseudoresistance
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fphar.2023.1140894/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!